Clinical trial NCT02010047: Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients
Official title: A Study to Compare the Performance of a qPCR-based Assay to Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH) in the Detection of Anaplastic Lymphoma Kinase (ALK) Fusion Mutations in Formalin Fixed Paraffin-embedded (FFPE) Tissue From Non-small Cell Lung Cancer (NSCLC) Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nonsmall Cell Lung Cancer
Keywords: Anaplastic lymphoma kinase gene
Polymerase chain reaction
Immunohistochemistry
Fluorescence in situ hybridization
Lead sponsor: British Columbia Cancer Agency
Sponsor class: OTHER
Collaborators: name: Insight Genetics
First posted: 2013-12-12
Enrollment: 166
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The anaplastic lymphoma kinase gene(ALK) is mutated approximately 5% of non-small cell lung cancers. Testing for this gene is important because there are drugs known as ALK inhibitors that have been shown to significantly delay the progression of ALK-mutated lung cancers. There are a number of ways to test for the presence of the ALK gene in lung cancer biopsy tissue. One method involves making slides and staining them to detect the ALK protein. This is called immunohistochemistry. Another method called fluorescence in situ hybridization(FISH)is used to detect rearrangements of the ALK gene associated with lung cancer. Although both these tests are widely used to test for ALK gene abnormalities, the techniques may not always find the ALK gene mutation because they are not sensitive enough or not enough cancer cells are present in the lung biopsy.

This study is being performed to determine if a technique called quantitation polymerase chain reaction (qPCR) is as accurate or better at finding the ALK gene mutation in lung cancer biopsy tissue.


Eligibility criteria: Inclusion Criteria:

* You have a confirmed diagnosis of non-squamous, non-endocrine non-small cell lung cancer.
* Your cancer biopsy has sufficient cancer cells to be tested for the (Epidermal Growth Factor Receptor (EGFR) mutation, the ALK fusion gene abnormality and the research ALK testing.
* Your lung cancer biopsy is determined not to have a mutation in the EGFR gene.
* You are 19 years old or older.
* You fully understand the study and give informed consent to participate as demonstrated by signing the consent.

Primary outcomes:
measure: To determine the true number of ALK positives and negatives of a qPCR assay for the detection in FFPE lung cancer biopsy specimens of ALK status in comparison with IHC and FISH ALK detection technologies.
timeFrame: Up to 24 weeks after the completing of enrollment of 72 ALK negative and 72 ALK positive tumor blocks
Secondary outcomes:
measure: The analysis of plasma and serum collected from those patients with ALK-positive NSCLC to assess the feasibility for the use of non-invasive sampling in the diagnosis and disease monitoring of lung cancer.
timeFrame: After completion of enrollemnt of 72 ALK postive tumor blocks.
Other outcomes:
Locations:
city: Abbotsford
country: Canada
facility: BC Cancer Agency-Abbotsford Centre
state: British Columbia
city: Kelowna
country: Canada
facility: BC Cancer Agency-Centre for the Southern Interior
state: British Columbia
city: North Vancouver
country: Canada
facility: Lions Gate Hospital
state: British Columbia
city: Prince George
country: Canada
facility: BC Cancer Agency-Centre for the North
state: British Columbia
city: Surrey
country: Canada
facility: BC Cancer Agency, Frase Valley Centre
state: British Columbia
city: Vancouver
country: Canada
facility: BC Cancer Agency, Vancouver Centre
state: British Columbia
city: Victoria
country: Canada
facility: BC Cancer Agency
state: British Columbia
Study officials:
affiliation: British Columbia Cancer Agency
name: David L Saltman, MD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: BC Cancer Agency, Molecular Diagnostic Laboraotry
name: Aly Karsan, MD
role: PRINCIPAL_INVESTIGATOR
References: